What's Happening?
GenScript has officially opened its first European mRNA production site in Delft, Netherlands, marking a significant expansion of its global mRNA platform. This new facility is part of GenScript's strategy to enhance its transatlantic biotechnology infrastructure,
providing greater regional proximity, regulatory alignment, and supply chain resilience for European innovators. The Delft site offers end-to-end mRNA workflow capabilities, including gene design, synthesis, and proprietary mRNA capping technology. This expansion follows GenScript's recent growth in the U.S. and reflects its commitment to building a resilient, high-quality growth platform that supports life science innovation.
Why It's Important?
The establishment of the Delft facility is crucial for GenScript's global strategy, as it enhances the company's ability to support European biotech innovation. By aligning with EU regulatory standards and integrating into GenScript's global quality systems, the site enables efficient movement from research-grade mRNA to development pathways. This expansion not only strengthens GenScript's position in the European market but also supports the broader biotech ecosystem by providing advanced mRNA technologies. The move is expected to facilitate faster collaboration and reduced shipping delays, benefiting both GenScript and its partners.
What's Next?
GenScript plans to continue expanding its innovation footprint across North America and Europe. The company aims to leverage its new European facility to enhance collaboration with local biotech innovators and academic institutions. By maintaining a unified global operating system, GenScript is poised to deliver greater speed and operational resilience for its partners. The company will likely focus on further integrating its global R&D and manufacturing network to support the development of next-generation therapies and vaccines.
